Bacteremia - Pipeline Insight, 2021

DelveInsight’s, “Bacteremia – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bacteremia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Bacteremia Understanding
Bacteremia: Overview
Bacteremia refers to the presence of live bacteria in the blood. Bacteremia may result from ordinary activities (such as vigorous toothbrushing), dental or medical procedures, or from infections (such as pneumonia or a urinary tract infection). Usually, bacteremia that results from ordinary events, such as dental procedures, is temporary and causes no symptoms. Bacteremia that results from other conditions may cause fever. Bacteremia may occur during: Certain ordinary activities, Dental or medical procedures, certain bacterial infections, and Injection of recreational drugs. Identifying or presuming the source of infection will dictate the diagnostic measures taken. People who are at high risk of complications due to bacteremia (such as those who have an artificial heart valve or joint or certain heart valve abnormalities) are often given antibiotics. Bacteremia requires urgent and appropriate antibiotics. Delay in the administration of appropriate antibiotics is associated with increased morbidity and mortality.

""Bacteremia - Pipeline Insight, 2021"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bacteremia pipeline landscape is provided which includes the disease overview and Bacteremia treatment guidelines. The assessment part of the report embraces, in depth Bacteremia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bacteremia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Bacteremia R&D. The therapies under development are focused on novel approaches to treat/improve Bacteremia.

Bacteremia Emerging Drugs Chapters
This segment of the Bacteremia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bacteremia Emerging Drugs
• Exebacase: ContraFect
Exebacase, a recombinantly-produced lysin, targets the peptidoglycan cell wall, which is vital to S. aureus bacteria. Exebacase has the potential to be the first-in-class of a new treatment for patients with Staph aureus bacteremia. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to exebacase (ContraFect) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. The drug is currently in Phase III stage of development for the treatment of patients with Bacteremia. Exebacase targets a highly conserved region of the cell wall that is vital to bacteria, thus making resistance less likely to develop. When used in combination with SOC antibiotics, the result is a novel treatment modality that has the potential to combat the high unmet clinical need of Staph aureus infections.

• Ceftobiprole medocaril: Basilea Pharmaceutica
Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp.3 The brand is currently approved and marketed as Zevtera and Mabelio in a number of countries in Europe and beyond. Basilea has entered into license and distribution agreements for the brand in Europe, Eurasian countries, Latin America, China, Canada, Israel, and the Middle East and North Africa (MENA) regions. A Phase III ERADICATE study, is evaluating the use of ceftobiprole for the treatment of patients with Staphylococcus aureus bacteremia.
Further product details are provided in the report……..

Bacteremia: Therapeutic Assessment
This segment of the report provides insights about the different Bacteremia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Bacteremia
There are approx. 10+ key companies which are developing the therapies for Bacteremia. The companies which have their Bacteremia drug candidates in the most advanced stage, i.e. Phase III include, ContraFect. Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Bacteremia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bacteremia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bacteremia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bacteremia drugs.

Bacteremia Report Insights
• Bacteremia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bacteremia Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Bacteremia drugs?
• How many Bacteremia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bacteremia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bacteremia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bacteremia and their status?
• What are the key designations that have been granted to the emerging drugs?